Table 3 Adverse events reported at follow-up
Adverse event reported, n (%) | ETN starters (n = 45) | ADA starters (n = 43) | P-value |
|---|---|---|---|
Fever | 1 (2.2%) | 0 (0.0%) | 1 |
Aphthae | 1 (2.2%) | 2 (4.7%) | 1 |
Gingivitis | 1 (2.2%) | 0 (0.0%) | 1 |
Headache | 3 (6.7%) | 4 (9.3%) | 1 |
Rash | 1 (2.2%) | 1 (2.3%) | 1 |
Mood swings | 1 (2.2%) | 5 (11.6%) | 0.20 |
Sleep disturbances | 0 (0.0%) | 5 (11.6%) | 0.06 |
Gastric complaints | 4 (8.9%) | 1 (2.3%) | 0.36 |
Nausea | 3 (6.7%) | 6 (14.0%) | 0.48 |
Vomiting | 1 (2.2%) | 1 (2.3%) | 1 |
Constipation | 1 (2.2%) | 0 (0.0%) | 1 |
Injection site reactions | 2 (4.4%) | 4 (9.3%) | 0.68 |
Dehydration | 1 (2.2%) | 0 (0.0% | 1 |
Hair loss | 0 (0.0%) | 2 (4.7%) | 0.24 |
Fatigue | 0 (0.0%) | 1 (2.3%) | 0.49 |
Urinary incontinence | 1 (2.2%) | 0 (0.0%) | 1 |
Leukopenia | 1 (2.2%) | 0 (0.0%) | 1 |